In vitro evalutation of a novel pan JAK/STAT inhibitor in asthma
Research type
Research Study
Full title
In vitro evaluation of a novel drug on airway epithelial cells obtained from participants with severe asthma
IRAS ID
182747
Contact name
Ian M Adcock
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
0 years, 5 months, 29 days
Research summary
Asthma is a long-term disease of the lungs. In asthma patients the sensitive airway tubes narrow in reaction to something that irritates the airways such as allergens or environmental pollutants. There is currently no cure for asthma and new medicines or combinations of medicines are needed that will be of benefit to patients particularly those with a more severe disease.
Activation of certain signal molecules inside the lung cells may participate in the development of asthma and the response to allergens. Blocking these signal molecules specifically with medicines might therefore be beneficial in the treatment of asthma.
In this study we want to test a new medicine that specifically targets a subset of signal molecules that are associated with the allergen response in the lung. In particular, we want to test this medicine on cells obtained from the lungs of asthma patients. Understanding the effects of this new medicine on these asthmatic lung cells will give vital information on how this new medicine works before we can test it in asthma patients.REC name
London - City & East Research Ethics Committee
REC reference
15/LO/1594
Date of REC Opinion
20 Nov 2015
REC opinion
Further Information Favourable Opinion